Genzyme Corporation (GENZ) Release: Synvisc Approved in Japan, Key Market for Viscosupplementation Products  
9/20/2010 10:34:25 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that Japan’s Ministry of Health, Labour and Welfare has approved Synvisc® (hylan G-F 20; 3 x 2 mL), indicated for the treatment of osteoarthritis of the knee. Reimbursement has been obtained and publicized by Japan’s Central Social Insurance Medical Council.